Vascular Endothelial Growth
Factor (VEGF) Antibodies Market Insights
On the basis of region, North
America and Europe are expected to show significant growth in the Vascular
Endothelial Growth Factor (VEGF) Antibodies Market over the forecast
period. North America has the presence of leading manufacturers who are
indulged in research and development of these therapies. Manufacturers such as
Novartis (Europe) and Genentech have these therapies in pipeline and are
expected to enter into the market over the forecast period. Asia Pacific region
is expected to show modest growth, owing to high costs of these therapies and
fairly low availability overall the region. Sophisticated insurance facilities
such as Medicaid and Medicare are not present in the developing economies due
to which patients cannot afford costly medical treatment in these regions.
However, insurance facilities are expected to drive growth of the market in
North America.
Vascular Endothelial Growth
Factor (VEGF) is a signal protein that helps in the formation of new blood
vessels through a process known as angiogenesis. Vascular endothelial growth
factor is a part of several pathological processes and researches are often
carried out for the development of novel therapies using these factors for
diseases such as cancer. Normal functions of vascular endothelial growth factor
includes embryonic development, formation of new blood vessels, and as a bypass
for a blocked vessel. However, overexpression of VEGF often culminates into
fatal disease such as cancerous cells. As solid tumors require additional blood
supply in order to keep functioning, the overexpression of VEGF serves that
purpose through angiogenesis. VEGF family has five members such as VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Out of these growth
factors, VEGF-A is responsible for angiogenesis and processes associated with
endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells,
which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has
been found to be associated with poor prognosis in various cancers, diabetic
retinopathy, and age-related macular degeneration. Therapeutic agents are
developed to inhibit the transduction pathways of vascular endothelial growth
factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine
kinase inhibitors inhibit the angiogenesis process and disease progression.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1614
Vascular Endothelial Growth
Factor (VEGF) Antibodies Market Drivers
Rising prevalence of diseases
such as cancer and macular degeneration is expected to boost growth of the
market over the forecast period. According to the American Cancer Society, in
2017, cancer was the second most common cause of death in the U.S., which
accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal
antibodies and angiogenesis inhibitors are highly specialized targeted
therapies, which directly targets the cancerous cells. The preference for
targeted therapies is rising, owing to the advantages (lesser side effects)
offered by targeted therapies over conventional therapies such as chemotherapy.
Furthermore, robust pipeline of VEGF antibodies is expected to boost the market
growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase
3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716
(Genentech) is in phase 2 trials, all indicated for age-related macular
degeneration. Moreover, Tecentriq manufactured by Roche received the U.S. FDA
priority review status to treat people with metastatic non-squamous non-small
cell lung cancer in May 2018. Therapies already present in the market have
shown improved clinical outcome in cancer as well as age-related macular
degeneration (AMD).
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/vascular-endothelial-growth-factor-antibodies-market-1614
For instance, Lucentis, as well
as Avastin have shown significant improvement in medical outcomes in associated
indications such as cancer. These therapies have spurred the interest of
manufacturers to further carry out research in this category, which is shown in
terms of number of agents present in the pipeline. Blockbuster drugs such as
Avastin and Lucentis allow manufacturers to invest in research and development
of such therapies, in order to generate the revenues later on while providing
the benefits to patients as well. These factors are expected to foster growth
of the market over the forecast period.
However, high costs of these
medications, biosimilar research, and subsequent launches are expected to
hamper the growth of the market. The U.S. Food & Drug Administration has
already approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin
(bevacizumab) in December 2017. Moreover, European Commission approved
biosimilar to Avastin (bevacizumab) in January 2018.
Key players operating in the
vascular endothelial growth factor (VEGF) antibodies market include Genentech,
Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG,
Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty
Ltd, and ThromboGenics, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1614
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment